Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection

NCT03269162 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

144

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Jinfukang Koufuye
DRUG: Docetaxel
DRUG: Pemetrexed
DRUG: Cisplatin

Sponsor

lihegen